Public Sector Pension Investment Board Bei Gene, Ltd. Transaction History

Public Sector Pension Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $29,304 - $53,912	200 Added 1.2%	16,898 $3.19 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $4.15 Million - $6.5 Million	16,698 New	16,698 $4.52 Million
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $4.46 Million - $6.38 Million	-20,144 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $160,803 - $243,474	850 Added 4.41%	20,144 $5.77 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $24,780 - $39,082	-200 Reduced 1.03%	19,294 $3.64 Million
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $146,208 - $207,828	1,200 Added 6.56%	19,494 $2.4 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $77,225 - $138,962	-667 Reduced 3.52%	18,294 $3.03 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $268,477 - $330,093	2,226 Added 13.3%	18,961 $2.32 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $442,053 - $569,523	3,878 Added 30.16%	16,735 $2.07 Million
Q1 2019 May 14, 2019	BUY	$122.82 - $151.83 $11,299 - $13,968	92 Added 0.72%	12,857 $1.7 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $1.37 Million - $2.24 Million	12,765 New	12,765 $1.79 Million

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Public Sector Pension Investment Board, based on Form 13F filings with the SEC.

Stay updated on Public Sector Pension Investment Board with notifications on news.